Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more e
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is ... the molecular diagnostics industry. BCC Research reveals in its new report that the market ... costs, and a growing need for better diagnostics as part of a molecular diagnostics ...
(Date:7/1/2015)... PALO ALTO, Calif. , July 1, 2015 ... company focused on the development of groundbreaking drugs ... sclerosis (ALS), announced today that Robert G. ... Research Center at Sutter Health,s California Pacific Medical ... from The ALS Association for $1.5 million to ...
(Date:7/1/2015)... 2015 Isagenix International, a leading global health ... three Silver, and three Bronze Stevie® Awards at the ... Chicago this month.The American Business ... program in the U.S. "Winning is ... developing leaders, cultivating talent, creating a unified team, and ...
(Date:7/1/2015)... 2015 InferMed , ... will augment ... clinical s olutions suite   Elsevier ... products and services, announced today the acquisition of  InferMed , ... technology company. InferMed,s Arezzo technology supports clinicians in ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... (Nasdaq: MNKD ) today announced that Matthew ... President and Chief Financial Officer,effective April 21, 2008. ... Chief Operating Officer, and will serve on MannKind,s,executive ... retirement of Dick Anderson, who has now transitioned ...
... (Nasdaq: KOSN ) presented data on its ... of target,specificity, strong binding affinity and potency, a ... and safety in murine xenograft,and orthotopic models., ... stabilize and/or activate a,number of proteins required for ...
... Laboratories, a national,clinical and anatomic pathology reference laboratory and ... that,company co-founder Carl R. Kjeldsberg, MD, will retire as ... Kjeldsberg has held the position,since 1993 and will continue ... Effective, July 1, 2009, Edward R. Ashwood, MD, ...
Cached Biology Technology:Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4ARUP Laboratories CEO and Co-Founder Announces Retirement 2
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... plate tectonics on Earth; Arctic Ocean,s role in the ... Olduvai Basin lake cycles and survival of early hominins; ... relationship between earthquakes and melting glaciers; monitoring Mt. Etna ... end of the PETM. The GSA TODAY science article ...
... in eastern Australia now have greater access to the ... NSW Department of Primary Industries (DPI). Trials undertaken ... cold storage at temperatures of 2 or 3C can ... 14 to16 days. Cold treatment at these temperatures ...
... declining food prices driven down by unprecedented advances in ... for wheat have tripled and those for maize and rice ... prices will fall soon. On the contrary, economists expect larger ... change and its devastating impacts on agriculture adding greatly to ...
Cached Biology News:December GEOLOGY and GSA TODAY media highlights 2December GEOLOGY and GSA TODAY media highlights 3December GEOLOGY and GSA TODAY media highlights 4December GEOLOGY and GSA TODAY media highlights 5December GEOLOGY and GSA TODAY media highlights 6December GEOLOGY and GSA TODAY media highlights 7December GEOLOGY and GSA TODAY media highlights 8December GEOLOGY and GSA TODAY media highlights 9December GEOLOGY and GSA TODAY media highlights 10Cold treatment opens doors for citrus exports to Japan 2Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers 2
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
PKC (pSer345), phospho-specific...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Biology Products: